Roger Crystal
Known title: DirectorCIK: 0001656633
Associated companies
Transaction History
| DFTX | ▲ Buy | Grant | 4,666 | $0 | 6/11/2026 | View on chart |
| DFTX | ▲ Buy | Grant | 13,671 | $0 | 6/21/2023 | View on chart |
| DFTX | ▲ Buy | Grant | 89,286 | $0 | 8/11/2022 | View on chart |
| DFTX | ▲ Buy | Grant | 4,666 | $0 | 6/11/2026 | View on chart |
| DFTX | ▲ Buy | Grant | 13,671 | $0 | 6/21/2023 | View on chart |
| DFTX | ▲ Buy | Grant | 89,286 | $0 | 8/11/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
JP Morgan Launches Coverage of DFTX with Overweight Rating
JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.
JP Morgan Launches Coverage of DFTX with Overweight Rating. JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.